Liminatus Pharma, Inc. (LIMN) Form 8-K — May 27, 2026
Liminatus Pharma, Inc. (LIMN) received a notice from Nasdaq confirming it failed to regain compliance with market value listing standards, triggering a delisting process. The company did not meet the $50 million Market Value of Listed Securities or the $15 million Market Value of Publicly Held Shares requirements by the May 18, 2026 deadline. Trading of the company’s common stock and warrants would have been suspended on May 29, 2026, had the company not filed an appeal.
Key figures
- Mvls requirement
- $50,000,000
- Mvphs requirement
- $15,000,000
- Compliance deadline
- May 18, 2026
- Suspension date if no appeal
- May 29, 2026
Price after filing
Close on the filing date to close N calendar days later (from $0.18). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.